Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 190-196

  Haralambos, K ^a   Whatley, S D ^b   Edwards, R ^b   Gingell, R ^b   Townsend, D ^b   Ashfield Watt, P ^a   Lansberg, P ^c   Datta, D B N ^b   McDowell, I F W ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^c Center for Translational Molecular Medicine Translational Research Infrastructure (CTMM TraIT)   (Netherlands)

Author keywords

Cholesterol; Criteria; Diagnosis; Familial hypercholesterolaemia; Genetics

Indexed keywords

ATORVASTATIN; DNA; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; GENETIC MARKER; HYPOCHOLESTEROLEMIC AGENT; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; UNITED KINGDOM; ADULT; AGED; BLOOD; FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATIENT SELECTION; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; BIOMARKERS; CHOLESTEROL, LDL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; PATIENT SELECTION; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RISK ASSESSMENT; RISK FACTORS; SERINE ENDOPEPTIDASES; TRIGLYCERIDES; WALES;

EID: 84924965687     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.003     Document Type: Article

References (35)

1. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolaemia. The Metabolic Basis of Inherited Disease 1995, 1981-2030. McGraw Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Lansberg P.J., Tuzgöl S., van de Ree M.A., Defesche J.C., Kastelein J.J. Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands. Ned. Tijdschr. Geneeskd. 2000, 144:1437-1440.
3. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J.Clin. Endocrinol. Metab. 2012, 97:3956-3964.
4. Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., Roeters van Lennep J.E., Stalenhoef A.F., Wiegman A., de Graaf J., Fouchier S.W., Kastelein J.J., Hovingh G.K. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. 2014, First published online 28 Feb 2014. 10.1093/eurheart/ehu058.
5. Stone N.J., Levy R.I., Fredrickson D.S., Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974, 49:476-488.
6. Datta B.N., McDowell I.F.W., Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr. Opin. Lipidol. 2010, 21:366-371.
7. National Institute of Health and Clinical Excellence Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: Identification and Management of Adults and Children with Familial Hypercholesterolaemia 2008, (Clinical Guideline 71).
8. National Institute of Health and Care Excellence Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia (NICE Diagnostics Guidance 2) 2011.
9. Sharma P., Boyers D., Boachie C., Stewart F., Miedzybrodzka Z., Simpson W., Kilonzo M., McNamee P., Mowatt G. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation. Health Technol. Assess. 2012, 17(17). 10.3310/hta16170.
10. McDowell I., Watson M., Townsend D., Featherstone K., Parham K., Whatley S. An evaluation of DNA diagnostics for familial hypercholesterolaemia including a study of personal and family implications [abstract]. Atherosclerosis 2007, 194:282.
11. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991, 303:893-896.
12. World Health Organization Familial Hypercholesterolemia - Report of a Second WHO Consultation 1999, World Health Organization, Geneva, Switzerland, (WHO publication no.WHO/HGN/FH/CONS/99.2).
13. Defesche J.C. Familial hypercholesterolaemia. Lipids and Vascular Disease 2000, 65-76. Martin Dunitz, London. D.J. Betteridge (Ed.).
14. Williams R.R., Hunt S.C., Schumacher M.C., Hegele R.A., Leppert M.F., Ludwig E.H., Hopkins P.N. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 1993, 72:171-176.
15. Damgaard D., Larsen M.L., Nissen P.H., Jensen J.M., Jensen H.K., Soerensen V.R., Jensen L.G., Faergeman O. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005, 180(1):155-160.
16. Clarke R.E., Padayachee S.T., Preston R., McMahon Z., Gordon M., Graham C., Crook M.A., Wierzbicki Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart 2013, 99(3):175-180.
17. Civeira F., Ros E., Jarauta E., Plana N., Zambon D., Puzo J., Martinez de Esteban J.P., Ferrando J., Zabala S., Almagro F., Gimeno J.A., Masana L., Pocovi M. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am. J. Cardiol. 2008, 102(9):1187-1193.
18. Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ. Cardiovasc. Genet. 2012, 5(3):354-359.
19. Harada-Shiba M., Arai H., Okamura T., Yokote K., Oikawa S., Nohara A., Okada T., Ohta T., Bujo H., Watanabe M., Wakatsuki A., Yamashita S. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J.Atheroscler. Thromb. 2012, 19(11):1019-1026.
20. Wallis Y., Payne S., McAnulty C., Bodmer D., Sistermans E., Robertson K., Moore D., Abbs S., Deans Z., Devereau A. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Medicine 2013, (Approved September 2013), Association for Clinical Genetic Science (ACGS), Dutch Society of Clinical Laboratory Specialists (VKGL).
21. Holm S. Asimple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6(2):65-70.
22. Mallett S., Halligan S., Thompson M., Collins G.S., Altman D.G. Interpreting diagnostic accuracy studies for patient care. BMJ 2012, 2:345-399.
23. Humphries S.E., Cranston T., Allen M., Middleton-Price H., Fernandez M.C., Senior V., Hawe E., Andrew Iversen A., Wray R., Crook M.A., Wierzbicki A.S. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J.Mol. Med. 2006, 84:203-214.
24. Naoumova R.P., Tosi I., Patel D., Neuwirth C., Horswell S.D., Marais A.D., van Heyningen C., Soutar A.K. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2654-2660.
25. Palacios L., Grandoso L., Cuevas N., Olano-Martín E., Martinez A., Tejedor D., Stef M. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 2012, 221:137-142.
26. Civeira F., Jarauta E., Cenarro A., García-Otín A.L., Tejedor D., Zambón D., Mallen M., Ros E., Pocoví M. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J.Am. Coll. Cardiol. 2008, 52(19):1546-1553.
27. Oostweveer D.M., Versmissen J., Yazdanpanah M., Hamza T.H., Sijbrands E.J.G. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis 2009, 207(2):311-317.
28. Bertolini S., Pisciotta L., Rabacchi C., Cefalù A.B., Noto D., Fasano T., Signori A., Fresa R., Averna M., Calandra S. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 2013, 227:342-348.
29. Bhatnagar D. Diagnosis and screening for familial hypercholesterolaemia: finding the patients, finding the genes. Ann. Clin. Biochem. 2006, 43(Pt 6):441-456.
30. Winder A.F., Jolleys J.C., Day L.B., Butowski P.F. Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia. Clin. Genet. 1998, 54(6):497-502.
31. Talmud P.J., Shah S., Whittall Futema M., Howard P., Cooper J.A., Harrison S.C., Li K., Drenos F., Karpe F., Neil H.A., Descamps O.S., Langenberg C., Lench N., Kivimaki M., Whittaker J., Hingorani A.D., Kumari M., Humphries S.E. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013, 381(9874):1293-1301.
32. Starr B., Hadfield G., Hutten B.A., Lansberg P.J., Leren T.P., Damgaard D.H., Neil A.W., Humphries S.E. Development of sensitive and specific age- and gender specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 2008, 46(6):791-803.
33. Koivisto P.V., Koivisto U.M., Miettinen T.A., Kontula K. Diagnosis of heterozygous familial hypercholesterolemia DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler. Thromb. Vasc. Biol. 1992, 12:584-592.
34. Leren T.P., Manshaus T., Skovholt U., Skodje T., Nossen I.E., Teie C., Sørensen S., Bakken K.S. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin. Vasc. Med. 2004, 4(1):75-85.
35. The Cardiac Society of Australia and New Zealand Guidelines for the Diagnosis and Management of FH 2013, The Cardiac Society of Australia and New Zealand. http://www.csanz.edu.au/wp-content/uploads/2013/12/Familial_Hypercholesterolemia_2013.pdf.